Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats

J Peripher Nerv Syst. 1999;4(3-4):211-21.

Abstract

The ability of neurotrophin-3 (NT-3) to reverse established nerve disorders was investigated in the peripheral neuraxis of streptozotocin-diabetic rats. Sciatic sensory and motor nerve conduction velocity deficits established after 2 months of diabetes were completely normalized by one further month of treatment with either NT-3 or insulin. None of these conduction velocity changes were associated with altered mean axonal caliber in the sciatic nerve. In the dorsal and ventral roots, mean axonal caliber was significantly decreased after 8 weeks of diabetes (both P < 0.05). Subsequently, one month of insulin, but not NT-3, treatment increased mean axonal caliber to age-matched control values. NT-3 treatment was also without effect on the significant (both P < 0.05) decrease in phosphorylated heavy neurofilament (NFH) subunits seen in dorsal and ventral roots of 12 week diabetic rats. In the sural nerve, diabetes attenuated a maturation-associated increase in mean axonal caliber over the first 8 weeks of diabetes, and induced atrophy between weeks 8 and 12 that was ameliorated by both NT-3 and insulin treatment. Reductions in sural nerve axonal caliber were associated with a tendency for elevation of both phosphorylated NFH levels in large fibers and the ratio of phosphorylated to nonphosphorylated NFH that was attenuated by NT-3. These data demonstrate that NT-3 corrects established sciatic nerve conduction deficits in diabetic rats in a manner independent of changes in axonal caliber in this nerve. Further, although NT-3 was without effect on decreases in axonal caliber and NFH subunit phosphorylation in the spinal roots, reversal of axonal caliber deficits in peripheral nerves of sensory fibers may involve NT-3-mediated normalization of aberrant neurofilament phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Axons / drug effects
  • Axons / physiology
  • Diabetes Mellitus, Experimental / physiopathology*
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / physiopathology*
  • Insulin / therapeutic use
  • Male
  • Nerve Fibers, Myelinated / drug effects
  • Nerve Fibers, Myelinated / pathology
  • Nerve Fibers, Myelinated / physiology*
  • Neural Conduction / drug effects*
  • Neurofilament Proteins / metabolism
  • Neurotrophin 3 / pharmacology
  • Neurotrophin 3 / therapeutic use*
  • Peroneal Nerve / drug effects
  • Peroneal Nerve / physiopathology
  • Phosphorylation
  • Rats
  • Rats, Wistar
  • Sciatic Nerve / drug effects
  • Sciatic Nerve / physiopathology
  • Spinal Nerve Roots / drug effects
  • Spinal Nerve Roots / physiopathology
  • Sural Nerve / drug effects
  • Sural Nerve / physiopathology

Substances

  • Insulin
  • Neurofilament Proteins
  • Neurotrophin 3